Subscribe to our newsletter to receive the latest product updates and special offers

HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite
Theme 		Help

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

SILO

SILO Pharma Inc

Last Close
Dec 05 • 04:00PM ET
1.40
Dollar change
-0.03
Percentage change
-2.34 		%
Scroll to Statements
Index- P/E- EPS (ttm)-1.35 Insider Own19.27% Shs Outstand3.16M Perf Week-15.87%
Market Cap4.34M Forward P/E- EPS next Y- Insider Trans1.69% Shs Float2.51M Perf Month-17.85%
Income-4.24M PEG- EPS next Q-0.20 Inst Own3.40% Short Float / Ratio2.02% / 0.53 Perf Quarter-32.06%
Sales0.07M P/S62.04 EPS this Y- Inst Trans- Short Interest0.05M Perf Half Y-37.66%
Book/sh2.41 P/B0.58 EPS next Y- ROA-38.50% Target Price10.00 Perf Year-60.21%
Cash/sh2.82 P/C0.50 EPS next 5Y- ROE-43.85% 52W Range1.22 - 6.56 Perf YTD-58.44%
Dividend- P/FCF- EPS past 5Y- ROI-56.59% 52W High-78.71% Beta-
Dividend %- Quick Ratio13.14 Sales past 5Y0.24% Gross Margin-1245.74% 52W Low14.82% ATR0.18
Employees3 Current Ratio13.14 Sales Q/Q0.00% Oper. Margin-6031.49% RSI (14)41.17 Volatility6.34% 11.99%
OptionableNo Debt/Eq0.00 EPS Q/Q56.78% Profit Margin-5883.80% Rel Volume0.15 Prev Close1.43
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume94.99K Price1.40
Recom1.00 SMA20-10.03% SMA50-9.44% SMA200-28.84% Volume13,911 Change-2.34%
Nov-21-23 08:01AM
Silo Pharma Enters into Exclusive License Agreement with Medspray Pharma BV for Intranasal Technology used in SPC-15 Treatment for PTSD
(GlobeNewswire) +12.93%
Nov-08-23 08:11AM
Silo Pharma to Initiate Dose-Ranging Study of Novel Intranasal Therapeutic SPC-15 for the Treatment of PTSD
(GlobeNewswire)
Oct-16-23 08:11AM
Silo Pharma's SPU-21 Peptide Shows Positive Results Against Rheumatoid Arthritis
(GlobeNewswire) -7.28%
Oct-11-23 08:35AM
Silo Pharma Initiates Human Factor Study of SPC-15 for the Treatment of PTSD
(GlobeNewswire)
Sep-20-23 08:28AM
Silo Pharma Announces Positive Data on SPC-15 for PTSD and Prepares to File Pre-Investigational New Drug (IND) Application with FDA
(GlobeNewswire)
08:50AM Loading…
Sep-12-23 08:50AM
Silo Pharma Initiates Feasibility Study of SPC-15 Novel Intranasal Formulation for PTSD
(GlobeNewswire)
Aug-10-23 08:50AM
Silo Pharma Engages Clarivate for Intellectual Property and Patent Management
(GlobeNewswire)
Aug-08-23 08:30AM
Silo Pharma Reaches Positive Milestone with Nasal Formulation of SPC-15 For Anxiety, PTSD, and Stress-Related Disorders
(GlobeNewswire)
Jun-23-23 09:00AM
Psychedelics Company Silo Pharma Working On Time-Release And Dosage Ketamine Implant And Topical, Hoping To Deliver Steady Pain Relief For Four Million Fibromyalgia Sufferers
(ACCESSWIRE)
Jun-21-23 09:00AM
Silo Pharmas SPU-21 Treatment for Autoimmune Disease Awarded U.S. Patent
(GlobeNewswire)
Jun-13-23 08:05AM
Silo Pharma Signs Agreement to Develop First-in-Class Ketamine Implant Therapeutic
(GlobeNewswire) -5.25%
Jun-02-23 08:50AM
Silo Pharma Announces Participation on Webull Corporate Communications Service Platform
(GlobeNewswire)
May-30-23 09:00AM
Silo Pharma Commences Study of Novel Joint Homing Peptide SPU-21
(GlobeNewswire)
May-09-23 08:05AM
Silo Pharmas SPC-15 Awarded U.S. Patent Protecting Ongoing R&D of Therapeutic for Stress-Induced Affective Disorder and Alzheimers Disease
(GlobeNewswire)
Apr-24-23 08:15AM
Silo Pharma to Present at Psychedelic Drug Development Conference
(GlobeNewswire)
09:00AM Loading…
Apr-19-23 09:00AM
Silo Pharma Commences Formulation for SPC-15 Targeting Anxiety and PTSD Stress-Related Disorders
(GlobeNewswire)
Mar-27-23 09:00AM
Silo Pharma Announces filing of Patent for Treatment of Fibromyalgia
(GlobeNewswire)
Mar-15-23 08:40AM
Silo Pharma Announces Positive Results from IND-Enabling Study of SP-26 for Fibromyalgia
(GlobeNewswire) -5.45%
Feb-13-23 08:35AM
Silo Pharma Announces Filing of Patent for Treatment of Alzheimers
(GlobeNewswire) +14.86%
Feb-02-23 08:50AM
Silo Pharma Announces Expansion of Intellectual Property Portfolio
(GlobeNewswire) +16.35%
Jan-31-23 07:45AM
Silo Pharma Announces Stock Repurchase Program
(GlobeNewswire) +6.37%
Jan-10-23 10:15AM
Silo Pharma Advances Clinical Study Analyzing Effects of Psilocybin on Inflammation
(GlobeNewswire)
Dec-30-22 08:10AM
Silo Pharma Announces Positive Study Results of SPU- 21 for Arthritis
(GlobeNewswire)
Dec-01-22 09:00AM
Silo Pharma Issues Letter to Shareholders Detailing Progress on Pipeline Assets Combining Traditional Therapeutics with Psychedelic Medicine
(GlobeNewswire)
Nov-21-22 07:45AM
Silo Pharma Initiates Study of Novel Joint Homing Peptide in Human Tissue
(GlobeNewswire)
Nov-11-22 08:15AM
Silo Pharma Achieves New Milestone for SP-26 Therapeutic -Initiates IND Enabling Study of Topical Ketamine Formulation
(GlobeNewswire) +6.75%
Oct-26-22 09:00AM
Silo Pharma to Discuss Mainstream Pharma and Psychedelics at Wonderland Miami Conference
(GlobeNewswire)
Oct-20-22 08:05AM
Silo Pharma Announces Data Supporting Therapeutic Potential of SPC-14 for Alzheimers Disease in Pre-Clinical Study
(GlobeNewswire) -12.97%
Oct-18-22 07:15AM
Silo Pharma extends research pact for Alzheimers and Stress Induced Anxiety Therapeutics
(GlobeNewswire)
Oct-10-22 08:05AM
Silo Pharma Initiates Toxicity Study of its Proprietary Ketamine Formulation for Treatment of Fibromyalgia
(GlobeNewswire)
08:20AM Loading…
Oct-06-22 08:20AM
Silo Pharma to Present at the Dawson James Small Cap Growth Conference on October 12
(GlobeNewswire)
Oct-03-22 09:47AM
Silo Pharma Initiates FDA Pre-Investigational New Drug (IND) Package for Time-Released Ketamine Technology
(GlobeNewswire)
Sep-30-22 08:30AM
Silo Pharma Announces Closing of $5.75 Million Public Offering of Common Stock, Nasdaq Listing, and Full Exercise of Underwriters Over-Allotment Option
(GlobeNewswire)
Sep-27-22 09:05AM
Silo Pharma Announces Uplisting to Nasdaq Capital Market and Pricing of $5 Million Public Offering of Common Stock
(GlobeNewswire) -24.56%
Sep-15-22 08:00AM
Silo Pharma Announces Implementation of 1-for-50 Reverse Stock Split in Preparation for Planned Uplisting to Nasdaq
(GlobeNewswire)
Jul-27-22 08:15AM
Silo Pharma Announces Positive Results from its Topically Administered Formulation of Ketamine
(GlobeNewswire)
Jul-12-22 11:23AM
Silo Pharma Announces Positive Results in Subcutaneous Delivery of its Novel Liposomes to Treat Arthritic Patients
(GlobeNewswire) +14.90%
Jun-23-22 08:05AM
Silo Pharma Expands License Agreement and Patent Portfolio
(GlobeNewswire) -14.29%
May-19-22 08:11AM
Silo Pharma Announces Successful Dosing of Patients Suffering from Parkinsons Disease in Psilocybin Study
(GlobeNewswire)
May-18-22 08:17AM
IBN (InvestorBrandNetwork) Announces Latest Episode of The Bell2Bell Podcast featuring Eric Weisblum, CEO of Silo Pharma Inc.
(GlobeNewswire)
Apr-20-22 08:10AM
Silo Pharma Produces SPU-21 Liposomes for Rheumatoid Arthritis Study
(GlobeNewswire) +6.45%
Mar-31-22 08:10AM
Silo Pharma Enters into Agreement with Contract Research Organization for Pharmacokinetic Study
(GlobeNewswire)
Silo Pharma, Inc. is a developmental stage biopharmaceutical company, which engages in the merging of traditional therapeutics with psychedelic research. It seeks to acquire and develop intellectual property or technology rights from universities and researchers to treat rare diseases, including the use of psychedelic drugs. The company was founded by Eric Weisblum on July 13, 2010 and is headquartered in Englewood Cliffs, NJ.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Weisblum EricCEO and PresidentNov 30Buy1.531,0001,530167,124Nov 30 09:10 PM
Weisblum EricCEO and PresidentNov 29Buy1.571,0001,570166,124Nov 30 09:10 PM
Weisblum EricCEO and PresidentNov 27Buy1.78250445165,124Nov 27 05:13 PM
Weisblum EricCEO and PresidentNov 22Buy1.68400672164,874Nov 27 05:13 PM
Weisblum EricCEO and PresidentNov 21Buy1.56300468164,474Nov 22 04:01 PM
Weisblum EricCEO and PresidentNov 20Buy1.604,0506,480164,174Nov 22 04:01 PM
Weisblum EricCEO and PresidentNov 17Buy1.541,8002,772160,124Nov 20 07:51 PM
Weisblum EricCEO and PresidentNov 16Buy1.331,1001,463158,324Nov 20 07:51 PM
Ryweck Daniel E.Chief Financial OfficerMay 26Buy2.131,0002,1265,000May 26 04:17 PM
Weisblum EricCEO and PresidentMay 18Buy2.115001,054157,724May 18 04:15 PM
Weisblum EricCEO and PresidentMay 17Buy2.062,5005,150157,224May 18 04:15 PM
Weisblum EricCEO and PresidentDec 20Buy2.72130354154,854Dec 20 07:07 PM
Weisblum EricCEO and PresidentDec 19Buy2.68200536154,724Dec 20 07:07 PM
Weisblum EricCEO and PresidentDec 14Buy3.17263834154,524Dec 15 04:15 PM
Weisblum EricCEO and PresidentDec 13Buy3.074871,494154,261Dec 15 04:15 PM
open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2023 FINVIZ.com. All Rights Reserved.